HER2-targeted therapies, prevalent in breast and gastric cancer, BCR-ABL inhibitors utilized for chronic myeloid leukemia (CML), and multiple myeloma therapies involving immunomodulatory drugs (IMID) and proteasome inhibitors are also able to provoke CTRCD [21–24]. The gene discussed is ERBB2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.